Vanin1 (VNN1) in chronic diseases: Future directions for targeted therapy

Eur J Pharmacol. 2023 Nov 30:176220. doi: 10.1016/j.ejphar.2023.176220. Online ahead of print.ABSTRACTVanin1 (VNN1) is an exogenous enzyme with pantetheinase activity that mainly exerts physiological functions through enzyme catalysis products, including pantothenic acid and cysteamine. In recent years, the crosstalk between VNN1 and metabolism and oxidative stress has attracted much attention. As a result of the ability of VNN1 to affect multiple metabolic pathways and oxidative stress to exacerbate or alleviate pathological processes, it has become a key component of disease progression. This review discusses the functions of VNN1 in glucolipid metabolism, cysteamine metabolism, and glutathione metabolism to provide perspectives on VNN1-targeted therapy for chronic diseases.PMID:38042463 | DOI:10.1016/j.ejphar.2023.176220
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research